Achieving New Heights! Congratulations to Bionime for Winning
the 2025 Taiwan Excellence Gold Award!
Bionime (4737-TW) continues to achieve great success. Its innovative product, RIGHTEST iFree CGM (Continuous Glucose Monitoring System), successfully entered major medical device channels in September this year. In October, it won the “Taipei Biotech Awards – Medical Device Innovation Technology Gold Award” and also received the “2025 Taiwan Excellence Gold Award,” proving the company’s outstanding R&D capabilities and innovative achievements are nationally recognized.
Product Highlights | A Revolutionary Tool for Blood Glucose Management
Rightest IFREE CGM is Taiwan’s first domestically-produced CGM product with manufacturing and sales approval. It overcomes the limitations of traditional blood glucose measurement by converting the single-stick testing method into a continuous, real-time monitoring system. Users can easily apply it themselves for up to 10 days of continuous monitoring, with data instantly transmitted to a mobile app, generating automated blood glucose management reports. This allows users, their families, and healthcare professionals to track glucose changes anytime, while also integrating lifestyle data such as diet, exercise, and medication. This helps users understand the reasons behind blood glucose fluctuations, enabling “safe blood sugar control, free living.”
Production Technology | Innovative Integrated Full-Process Technology
The success of the Rightest IFREE CGM is a result of nearly ten years of R&D investment by Bionime. The product has filed over 400 global patents and has received 237 international patents. Bionime’s in-house CGM production covers over 200 production processes and is equipped with more than 100 automated machines and AOI inspection systems. The integration of CIM+MES intelligent manufacturing management systems has achieved Industry 4.0 automation standards.
Corporate Mission and Development Direction
Bionime is committed to promoting the widespread adoption of CGM technology in Taiwan. Recently, it held “Rightest IFREE CGM Product Launch Conferences” in Taipei, Taichung, and Kaohsiung, attracting nearly a thousand diabetes professionals to discuss the opportunities and challenges of CGM in clinical care. Upholding a 6σ corporate culture, Bionime strives for excellent quality while maintaining affordability, aiming to make CGM products accessible for every diabetic patient and realize the vision of “safe blood sugar control, free living.”
